The authors concluded, "Treatment with GLP-1 receptor agonists was associated with lower all-cause mortality among patients with type 2 diabetes, advanced-stage CKD, and ESKD than was treatment with DPP-4 inhibitors
The drug or biologic administered is billed separately using the appropriate HCPCS Level II J-code (e.g., J0290 for ampicillin, J1040 for methylprednisolone, J0135 for adalimumab)
We also report that 13% of patients with type 1 diabetes in our registry use adjuvant glucose-lowering therapy in addition to insulin, significantly higher than the 5.4% reported from the T1D Exchange Registry in the US [18]
*Journal of the International Society of Sports Nutrition, 14*(1), Article 18
Esophageal reconstruction with alternative conduits
McCall McPhereson: Yeah, this is the most fascinating thing that I've encountered in medicine maybe ever, but